Infantile hemangioma: pathogenesis and mechanisms of action of propranolol
- 28 November 2017
- journal article
- review article
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 15 (12), 1185-1190
- https://doi.org/10.1111/ddg.13365
Abstract
Infantile hemangioma (IH) is the most common benign tumor of childhood, with a prevalence of 4 % to 10 %. It is characterized by a proliferative rapid growth phase, which starts after a few weeks of life, followed by a slow regression phase. In IH cases that are potentially disfiguring or life-threatening (10 % to 15 % of all cases), systemic therapy should be promptly initiated. The present study reviews published scientific articles available in reliable electronic databases. Selected were all studies that evaluated the pathogenesis of IH and the mechanisms of action of propranolol. The pathogenesis of IH has not been fully elucidated. Studies show that, in the proliferative phase of IH, there is an imbalance of angiogenic factors and an increase in the levels of vascular endothelial growth factor and matrix metalloproteinases 2 and 9. In the regression phase, the levels of these factors decrease, whereas those of antiangiogenic factors, including tissue inhibitors of matrix metalloproteinases, increase. Since 2008, propranolol has become the drug of choice in the treatment of IH, targeting vascular tone, angiogenesis, and apoptosis. Current insights into the pathogenesis of IH allow for the development of new therapeutic strategies.Keywords
This publication has 47 references indexed in Scilit:
- Serum‐Level Changes of Vascular Endothelial Growth Factor in Children with Infantile Hemangioma after Oral Propranolol TherapyPediatric Dermatology, 2013
- Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patientsBritish Journal of Oral and Maxillofacial Surgery, 2013
- Urinary matrix metalloproteinases-2/9 in healthy infants and haemangioma patients prior to and during propranolol therapyEuropean Journal of Pediatrics, 2011
- A Prospective Study of Infantile Hemangiomas with a Focus on Incidence and Risk FactorsPediatric Dermatology, 2011
- Infantile Hemangioma--Mechanism(s) of Drug Action on a Vascular TumorCold Spring Harbor Perspectives in Medicine, 2011
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Corticosteroid Suppression of VEGF-A in Infantile Hemangioma-Derived Stem CellsThe New England Journal of Medicine, 2010
- Vasculogenesis in infantile hemangiomaAngiogenesis, 2009
- Proliferation hemangiomas formation through dual mechanism of vascular endothelial growth factor mediated endothelial progenitor cells proliferation and mobilization through matrix metalloproteinases 9Medical Hypotheses, 2008
- Progress in matrix metalloproteinase researchMolecular Aspects of Medicine, 2008